- Global Pharma News & Resources

BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 at 8am Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Interested parties can access a live audio webcast on the Events and Presentations section of BioTime’s website. An archived presentation will be available on the website for 30 days. Conference updates can be found on the LD Micro website and directly via Twitter (@theLDMicro).

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime’s lead cell delivery clinical program is Renevia®, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, FacebookYouTube, and Google+. To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list:

View source version on

Editor Details

Last Updated: 29-Nov-2018